SEGMENT INFORMATION

6 Months Ended

Jun. 30, 2025

Segment Reporting [Abstract]

SEGMENT INFORMATION

NOTE 14: SEGMENT INFORMATION  

The Company has one operating and reporting segment, that develops, manufactures and markets products for the treatment of carotid artery disease and other vascular disease, including the Company’s proprietary CGuard™ stent platform. The Company’s Chief Operating Decision Maker (“CODM”), who is the CEO evaluates the Company’s performance based on its internal reporting which is consistent with the presentation in the Company’s consolidated financial statements. Accordingly, our CODM uses consolidated net income to measure segment profit or loss, allocate resources, and assess performance.

The CODM examines, within each operational function the employee salaries including the bonus and share based compensation. In addition, the CODM examines the clinical trials expenses within the research and development operations.

	Three months ended June 30,						Six months ended June 30,
	2025			2024			2025			2024
Revenues		1,778			1,739			3,307			3,250
Cost of Revenues:
Material and Labor		1,138			1,192			2,163			2,164
Other cost of revenues		327			216			539			463
Total Cost of Revenues		1,465			1,408			2,702			2,627
Research and development (R&D)
Payroll and Benefits		1,120			668			1,974			1,351
Share based compensation		645			682			1,314			1,151
Clinical trials		1,125			1,166			2,287			1,949
Other R&D		944			885			2,318			1,575
Total Research and development		3,834			3,401			7,893			6,026
Selling and marketing (S&M)
Payroll and Benefits		2,779			793			4,757			1,615
Share based compensation		595			264			812			514
Other S&M		798			388			1,353			553
Total Selling and marketing		4,172			1,445			6,922			2,682
General and administrative (G&A)
Payroll and Benefits		1,729			818			3,309			1,648
Share based compensation		1,920			1,726			3,700			3,510
Other G&A		1,677			1,201			3,260			2,431
Total General and administrative		5,326			3,745			10,269			7,589
Financial Income (expenses), net;		(132	)		351			162			733
Segment net Loss		(13,151	)		(7,909	)		(24,317	)		(14,941	)